Navigation Links
Metabolex Initiates Phase 1 Trial of MBX-2982
Date:3/26/2008

- Potential First-in-Class Treatment for Type 2 Diabetes -

HAYWARD, Calif., March 26 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has dosed the first cohort of healthy subjects in a Phase 1 clinical trial of MBX-2982, a potential first-in-class treatment for type 2 diabetes.

The Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of MBX-2982. Investigators expect to enroll a total of 60 healthy volunteers in the 6-cohort ascending-dose study.

MBX-2982 is an agonist of GPR119, a G-protein coupled receptor (GPCR) that is expressed in pancreatic islets and the gastrointestinal tract. Pre-clinical studies conducted by Metabolex and others show that GPR119 agonists can stimulate glucose-dependent insulin secretion and may preserve beta cell health -- properties that mimic incretins such as GLP-1, and exenatide (a GLP-1 analogue marketed as Byetta(R)). Unlike exenatide, however, MBX-2982 can be delivered orally. In addition, MBX-2982 may provide additional benefit when used in combination with a DPP-4 inhibitor such as sitagliptin (Januvia(R)), or other oral therapies.

"We have identified a number of potent GPR119 agonists that improve glucose control in normal and diabetic animal models," said David B. Karpf, MD, chief medical officer of Metabolex. "Advancing MBX-2982 into Phase 1 represents a significant achievement in the expansion of our clinical pipeline and further validates our research and development capabilities."

About Diabetes

Diabetes is a worldwide health problem and a rapidly growing source of illness, death and health care costs. According to the International Diabetes Federation, approximately 230 million people, or almost 6 percent of the world's population, had diabetes in 2006. The American Diabet
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... and NEW PROVIDENCE, N.J. , July ... are invited to meet with Linde,s Healthcare division ... to be held at McCormick Place in ... "Hospitals demand nothing less than complete confidence in ... , Linde,s Healthcare Segment manager. "Linde understands the importance ...
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
(Date:7/28/2014)... , July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Second Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, ... PTWhere: www.isispharm.com How:Live on the Internet. Simply log ... to participate during the live event, a replay of ... at www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, ...
Breaking Medicine Technology:Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... 17, 2011 Reportlinker.com announces that a ... its catalogue: Depression Therapeutics ... 2018 http://www.reportlinker.com/p0656880/Depression-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Market Forecasts to 2018 ...
... Par Pharmaceutical, Inc., the wholly-owned subsidiary of Par ... announced that it filed a declaratory judgment complaint and ... in Washington, D.C. seeking to preserve Par,s First Amendment ... healthcare providers about the FDA-approved, on-label use of Par,s ...
Cached Medicine Technology:Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 2Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 3Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 4Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 5Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 6Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 7Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 8Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 9Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 10Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 2Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 3Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 4
(Date:7/28/2014)... 2014 This is a professional ... Tadalafil industry. The report firstly reviews the basic ... manufacturing technology. The report then explores global and ... specification, capacity, Production value, and market share etc. ... and China’s total market of Tadalafil by calculation ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Mahendra Trivedi, ... hosted the Trivedi Online Workshop ‘Consciousness is Power’ on ... (EST). During this workshop, participants from all over the ... of making a deeper connection to their inner guidance ... participants explored the various advantages of raising consciousness and ...
(Date:7/28/2014)... 2014 Scientists in Japan have completed ... blood test for the asbestos cancer mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Juntendo University Graduate School of Medicine say a new ... step above the old test. , “Particularly for ...
(Date:7/28/2014)... Wisconsin (PRWEB) July 28, 2014 ... business process outsourcing (BPO) for Fortune 500 brands, announced ... jobs across its locations in Wisconsin, California, Florida and ... be based at its Neenah campus. , A majority ... which have seasonal ramp-ups that require additional staffing in ...
(Date:7/28/2014)... Community Health Center of Snohomish County (CHC), ... services, has released an article designed to educate patients ... Founded in 1983, the health center has a strong ... that face barriers to obtaining high quality yet affordable ... the CHC, click here: http://www.chcsno.org/locations.ashx?p=1099 , The ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 4Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 3Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 3Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 3
... nerve fibers regenerate, researchers say , FRIDAY, Dec. 11 (HealthDay ... enables regeneration of injured nerve fibers (axons) in mice, a ... treatments for people with brain and spinal cord injuries. , ... an inhibitor of a growth pathway called mTOR -- in ...
... H1N1 activity, down from 25 states last week, CDC says ... rates continue to drop, U.S. health officials said Friday, with ... states last week and 48 states at the height of ... influenza viruses identified so far continue to be H1N1 swine ...
... , , ABBOTT PARK, Ill., Dec. 11 ... declared a quarterly common dividend of 40 cents per share. , ... since 1924. The cash dividend is payable Feb. 15, 2010, to ... , Abbott has increased its dividend payout for 37 consecutive years - ...
... , , Linton Whitaker, ... 11 Linton Whitaker, M.D., a craniofacial surgeon at The ... recently awarded the prestigious Paul Tessier Medal during the annual ... England. , The Paul Tessier Medal is the highest honor ...
... , , AUSTIN, Texas, ... Medical Solutions, is pleased to offer free upgrades to their customers ... Dragon Medical 10.1 is faster and more stable, providing up ... and is compliant with Windows7, 64bit and 32bit operating systems. New ...
... Ill., Dec. 11 If you have a foot or ankle ... every five Americans suffer some sort of foot problem. These problems ... as pain in the knee, hip or back. , How ... If they hurt, they may be signaling more serious conditions. They ...
Cached Medicine News:Health News:New Hope for Brain, Spinal Cord Injuries 2Health News:Swine Flu Infection Rates Continue to Fall 2Health News:Swine Flu Infection Rates Continue to Fall 3Health News:Children's Hospital Surgeon Receives Prestigious Paul Tessier Medal 2Health News:Recorders.com Offers Free Dragon Medical 10.1 Upgrades 2Health News:Happy Feet are Healthy Feet: Common Sense Tips on Taking Care of Your Feet to Survive the Holiday Season 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: